ANMAT clinical-trial submission checklist for medical device studies in Argentina

Sponsors keep asking what ANMAT requires for clinical trials in Argentina as if one ninety-day bar covered ethics, investigation authorization, investigational import, and later commercial registro. It does not. ANMAT is one agency name on two files. Confusing them is how an Argentina Gantt goes soft.

I am Julio Martinez-Clark, CEO of bioaccess®. This checklist is for medical-device clinical-investigation filings in Argentina. It is grounded in the live ANMAT trial authorization vs registro post, the investigational import guide, and the market-access hub. It is not a quote and not legal advice. Confirm every instrument against ANMAT’s current published texts before you file.

Separate the two ANMAT files first

Write two columns on one page before translators start:

Investigation file. ANMAT clinical-investigation authorization for a first-in-human (FIH) or early feasibility study (EFS), plus independent ethics review under ISO 14155 and the Declaration of Helsinki, and provincial oversight where it applies (for example Buenos Aires). Success criterion: authorized research use of the named investigational article.
Registro file (commercial, later or parallel only if truly in scope). Sanitary registration for Classes I–IV under Disposición ANMAT N° 64/2025, including the simplified declaración jurada (DDJJ) route for CE-marked Class I/II through HELENA, with a local authorized representative / Technical Director ANMAT will treat as responsible for that certificate. Success criterion: a selling license — not a trial letter.

If the board slide says “ANMAT approved,” ask which ANMAT. Trial authorization is not a selling license.

Governing desks on the investigation track

ANMAT — Dirección de Investigación Clínica. Disposición ANMAT 7516/2025 Article 5 assigns clinical-investigation evaluation to that directorate. The Colombia execution pillar already notes that disposition states no binding day-count for that evaluation desk in the same way some markets publish one; Argentina’s published planning framework for device investigations on our Argentina trial page remains the 90-business-day statutory review target that pauses for RFIs. FIH/EFS device studies often exceed that target. Treat 90 business days as a planning framework, not a guaranteed total start-up time.
Independent ethics committee. Protocol, Spanish informed consent, and investigator packet. Ethics is a gate on the trial track, not a commercial license.
Provincial oversight where required. File federal, ethics, and provincial packages in parallel when the study design allows it. Sequential filing adds calendar the statutory target never promised to absorb.
Investigational import. Authorization linked to the ANMAT trial approval, through a licensed importer of record, with a device-level manifest. A commercial registro number does not clear investigational kits. Argentina’s import documentation is exacting — reconcile every document before filing (see the regional import guide).

Submission checklist (investigation dossier)

Assemble the universal FIH core once, then layer Argentina’s desks. Do not invent form codes that are not on the live bioaccessla.com pages — use this operator checklist against ANMAT’s current published requirements at filing time.

Section	What to freeze	Operator check
Protocol	Version, endpoints, stopping rules, schedule of events	Same version across ANMAT, ethics, and provincial packs
Investigator’s brochure / preclinical	Risk profile for first human use	Matches the article on the investigational device list
Informed consent (Spanish)	Ethics-ready language for Argentina	Not the commercial IFU you will later lock on a registro
Case report form	Locked before site training	Version matches protocol
Insurance	Trial-related injury coverage in the form Argentina requires	Territory and named parties match the sites
ISO 14155 monitoring plan	GCP bridge for foreign data	If U.S. filing is intended, design for 21 CFR § 812.28 inspectability from day one
Investigational labeling	For clinical investigation only	Lot/serial traceability matches site accountability
Device / accessory list	Every unit that will sit in the accountability log	Quantities match what import will request
Importer of record	Legal name before ethics stamps the protocol	Document ties shipment to investigation authorization — not HELENA DDJJ, not a cousin SKU’s registro
Ethics + provincial letters	Independent committee; provincial filings where required	Keep correspondence in one trial master file

What this checklist is not

It is not the commercial Classes I–IV / HELENA map under Disposición 64/2025. That is the market-access track and the live ANMAT registration checklist.
It is not an importer-of-record substitute for a sanitary registration holder. Argentina is a strict single-IoR example on the commercial track (authorized representative under Disp. 64/2025). That holder conversation belongs on market access. It does not clear investigational freight for a FIH.
It does not claim ANMAT is a PAHO/WHO Level 4 authority, and it does not invent an ICH-member claim — those claims are not published on this site.

Import: investigational units are not the registro SKU

Name the trial importer before ethics stamps the protocol. Map every investigational model, accessory, and spare to the investigation-authorized list. Outer labels must read as investigational. After last patient, close investigational inventory under the trial rules. Leaving units “for the hospital” without a new sanitary path is a new regulatory event, not a courtesy.

Hand-carry is not the plan. Formal, traceable importation tied to the trial authorization is required across Latin America; Argentina is not an exception.

If the Argentina FIH must support a U.S. file

Design the investigation so the evidence room can satisfy 21 CFR § 812.28 (acceptance of data from clinical investigations conducted outside the United States): GCP, independent ethics review, and a device comparable to the version you will put in front of FDA. ISO 14155 is the device GCP bridge FDA has publicly recognized for foreign investigations. A clean ANMAT investigation letter does not replace an inspectable trial master file. Keep device accountability, deviation logs, monitoring reports, ethics correspondence, and provincial letters in one place from day one. Eligibility of foreign data under § 812.28 is not a clearance prediction.

Common rejection / delay patterns

One 90-day bar for both desks. Treating the statutory trial review target as if it also covered Classes I–IV commercial registration. Higher-risk commercial work often runs several months on experience, not on the trial clock.
Registro number on investigational freight. Using a commercial ANMAT certificate for a predicate or related model to move FIH units.
One Spanish translation for both desks. Ethics/investigation language is not the commercial IFU ANMAT will later lock on a registro.
Importer named after first patient. Import documentation then becomes the critical path the ethics letter cannot fix.
RFI pause ignored on the Gantt. The 90-business-day target pauses for requests for information. Budget response time.

One-page gate before first patient in Argentina

Authority map: ANMAT investigation + independent ethics (+ provincial where required) versus commercial registro under Disp. 64/2025 / HELENA only if launch is truly in scope this year.
Same protocol version and same Spanish informed-consent text across federal, ethics, and provincial packages.
Investigational importer named, with the document that ties the shipment to the investigation authorization.
Device list complete, including accessories.
ISO 14155 file owner who can produce monitoring, accountability, and ethics letters within 48 hours if FDA or a notified body asks.
Commercial holder (optional, separate): Argentine authorized representative / Technical Director kept off the FIH critical path until first patient is locked.

Frequently asked questions

What are ANMAT requirements for clinical trials in Argentina?

For devices, expect an ANMAT clinical-investigation file evaluated via the Dirección de Investigación Clínica (Disposición 7516/2025 Art. 5), independent ethics review, provincial filings where required, investigational labeling and import tied to the trial authorization, and an ISO 14155-ready trial master file. Commercial registro under Disposición 64/2025 / HELENA is a second petition.

Does the 90-business-day clock cover commercial registration?

No. The 90-business-day statutory target on our Argentina investigation pages is a planning framework for the trial review that pauses for RFIs. Classes I–IV registro is a separate file and clock.

Can we use a commercial ANMAT number to import FIH units?

No. Investigational units need import authorization linked to the trial approval. A registro number for a related commercial SKU does not clear the investigational article.

Is the registration holder the same as the trial importer?

Not automatically. Argentina’s commercial track is a strict single-IoR / authorized-representative posture under Disp. 64/2025. Name the trial importer for the investigation; keep the sanitary registration holder on the market-access track.

Will FDA accept Argentina FIH data?

Foreign clinical data may be eligible for FDA consideration under 21 CFR § 812.28 when GCP, ethics, and device comparability are documented. Eligibility is not a clearance or approval prediction.